JR
Therapeutic Areas
Swedish Orphan Biovitrum Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BIVV001 (rFVIIIFc-VWF-XTEN) | Hemophilia A | Phase 3 |
| Doptelet (avatrombopag) | Chronic Immune Thrombocytopenia (ITP) | Marketed / Phase 4 |
| Gamifant (emapalumab) | Primary Hemophagocytic Lymphohistiocytosis (HLH) | Marketed / Phase 2/3 |
| Kineret (anakinra) | Autoinflammatory Diseases (e.g., CAPS, FMF) | Marketed |
| SEL-212 | Refractory Gout | Phase 3 |
Leadership Team at Swedish Orphan Biovitrum
GO
Guido Oelkers
Chief Executive Officer and President
RL
Rami Levin
EVP, Chief Commercial Officer
HS
Henrik Stenqvist
EVP, Chief Financial Officer
KF
Karin Fischer
EVP, People & Culture
AU
Anders Ullman
EVP, Medical & Scientific Affairs